Moreover, elegant experiments have provided evidence for CCL22’s oncogenic role in multiple types of cancers: CCL22 overexpression renders an immunosuppressive TME and is associated shortened OS for cervical cancer patients (Ni et al., 2022); the intimate association between CCL22 and disease progression was revealed in esophageal cancer patients (Chen J. et al, 2022). This evidence concerns the gene CCL22 and cervical cancer.